Has Nadia Hansel, MD received payments from drug or device companies?

Yes. Drug and device makers reported $90,071 in general payments to Nadia Hansel, MD across 63 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Nadia Hansel, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Nadia Hansel, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Nadia Hansel, MD

Pulmonary Disease · Baltimore, MDNPI 1447209465

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $82,062 of the $90,071 with a category attached, or 91.1%. 5 manufacturers reported payments, led by Sanofi at 44.1% of the total. 2025 is the largest year on record at $42,425, 4.3 times the $9,807 reported in 2020. Among pulmonary disease clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$90,071in general payments, 2019–2025

Across 63 payments — averaging $1429.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$40K
AstraZeneca$17K
GSK$16K
Genentech USA, Inc.$13K
Regeneron$5K

$186,896in research payments, 2019–2025

Across 69 payments — averaging $2708.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Boehringer Ingelheim$126K
AstraZeneca$53K
Sanofi$4K
Boehringer Ingelheim Pharma GmbH & Co.kg$4K

What the payments were for

Consulting fees$82,06291%
Travel & lodging$5,4696%
Food & beverage$2,5403%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	18	$39,700
AstraZeneca	21	$17,303
GSK	3	$15,600
Genentech USA, Inc.	13	$12,658
Regeneron	8	$4,810

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$90,071 in reported general payments places this provider in the 90th percentile of 297 pulmonary disease providers in Maryland.

See all pulmonary disease providers in Maryland →

Medicare billing

Part B allowed, 2024

$8,172

Medicare patients

Services billed

100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dupixent PenDupilumab	18	$73,531
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	32	$30,015
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr	24	$12,660
Breo ElliptaFluticasone/Vilanterol	14	$7,604
SymbicortBudesonide/Formoterol Fumarate	12	$5,880
Albuterol Sulfate HfaAlbuterol Sulfate	18	$1,066
Fluticasone Propionate	12	$274
Prednisone	25	$126

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta	$15,600	$50,27970 claims
AstraZenecaSymbicort	$17,303	$5,88012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 297 pulmonary disease providers in Maryland.

Other pulmonary disease in Baltimore

Alan SchwartzBaltimore$1.3M
Hitesh BatraBaltimore$611K
Lonny YarmusBaltimore$582K
Robert WiseBaltimore$389K
Ko Pen WangBaltimore$280K
Hans LeeBaltimore$277K
Angela ArgentoBaltimore$269K
Michael DrummondBaltimore$263K
Jason AkulianBaltimore$231K
Kathryn RobinettBaltimore$160K

See the full list for Maryland →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →